A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs BMS-986263 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Nitto Denko
- 01 Jun 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 1 Jun 2018.
- 29 May 2018 Status changed from not yet recruiting to recruiting.
- 23 May 2018 New trial record